JP7119114B2 - 潰瘍性大腸炎を治療する方法 - Google Patents

潰瘍性大腸炎を治療する方法 Download PDF

Info

Publication number
JP7119114B2
JP7119114B2 JP2020552872A JP2020552872A JP7119114B2 JP 7119114 B2 JP7119114 B2 JP 7119114B2 JP 2020552872 A JP2020552872 A JP 2020552872A JP 2020552872 A JP2020552872 A JP 2020552872A JP 7119114 B2 JP7119114 B2 JP 7119114B2
Authority
JP
Japan
Prior art keywords
administered
dose
milikizumab
maintenance
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020552872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517156A5 (enExample
JP2021517156A (ja
Inventor
ジェイムズ・ベネディクト・キャナバン
スチュアート・ウィリアム・フリードリック
キャスリン・アン・クルーガー
キャサリン・ミルチ
ジェイ・ローレンス・タットル
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2021517156A publication Critical patent/JP2021517156A/ja
Publication of JP2021517156A5 publication Critical patent/JP2021517156A5/ja
Priority to JP2022123689A priority Critical patent/JP7331219B2/ja
Application granted granted Critical
Publication of JP7119114B2 publication Critical patent/JP7119114B2/ja
Priority to JP2023130117A priority patent/JP7571225B2/ja
Priority to JP2024176901A priority patent/JP2025020134A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020552872A 2018-03-30 2019-03-28 潰瘍性大腸炎を治療する方法 Active JP7119114B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022123689A JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法
JP2023130117A JP7571225B2 (ja) 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法
JP2024176901A JP2025020134A (ja) 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
US62/650,314 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022123689A Division JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法

Publications (3)

Publication Number Publication Date
JP2021517156A JP2021517156A (ja) 2021-07-15
JP2021517156A5 JP2021517156A5 (enExample) 2021-08-26
JP7119114B2 true JP7119114B2 (ja) 2022-08-16

Family

ID=66429483

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020552872A Active JP7119114B2 (ja) 2018-03-30 2019-03-28 潰瘍性大腸炎を治療する方法
JP2022123689A Active JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法
JP2023130117A Active JP7571225B2 (ja) 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法
JP2024176901A Pending JP2025020134A (ja) 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022123689A Active JP7331219B2 (ja) 2018-03-30 2022-08-03 潰瘍性大腸炎を治療する方法
JP2023130117A Active JP7571225B2 (ja) 2018-03-30 2023-08-09 潰瘍性大腸炎を治療する方法
JP2024176901A Pending JP2025020134A (ja) 2018-03-30 2024-10-09 潰瘍性大腸炎を治療する方法

Country Status (29)

Country Link
US (2) US12152072B2 (enExample)
EP (2) EP3773715B1 (enExample)
JP (4) JP7119114B2 (enExample)
KR (1) KR102552693B1 (enExample)
CN (1) CN111936165A (enExample)
AU (2) AU2019243283C1 (enExample)
BR (1) BR112020018099A2 (enExample)
CA (1) CA3095297A1 (enExample)
DK (1) DK3773715T3 (enExample)
EA (1) EA202091989A1 (enExample)
ES (1) ES2983809T3 (enExample)
FI (1) FI3773715T3 (enExample)
HR (1) HRP20240904T1 (enExample)
HU (1) HUE067445T2 (enExample)
IL (2) IL277514B2 (enExample)
LT (1) LT3773715T (enExample)
MA (1) MA52216B1 (enExample)
MD (1) MD3773715T2 (enExample)
MX (1) MX2020010269A (enExample)
MY (1) MY202368A (enExample)
PL (1) PL3773715T3 (enExample)
PT (1) PT3773715T (enExample)
RS (1) RS65661B1 (enExample)
SG (1) SG11202009526RA (enExample)
SI (1) SI3773715T1 (enExample)
TW (2) TWI837532B (enExample)
UA (1) UA128578C2 (enExample)
WO (1) WO2019191464A1 (enExample)
ZA (1) ZA202005388B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
KR20220141847A (ko) * 2020-02-14 2022-10-20 얀센 바이오테크 인코포레이티드 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
TW202241506A (zh) * 2021-01-06 2022-11-01 美商艾伯維有限公司 治療克羅恩氏病及潰瘍性結腸炎之方法
JP2024520202A (ja) * 2021-05-20 2024-05-22 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患を治療する方法
EP4347018A1 (en) * 2021-05-28 2024-04-10 Eli Lilly and Company Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
WO2024110898A1 (en) * 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
KR20250156783A (ko) 2023-03-10 2025-11-03 일라이 릴리 앤드 캄파니 궤양성 결장염을 치료하는 방법
TW202500185A (zh) * 2023-06-16 2025-01-01 大陸商信達生物製藥（蘇州）有限公司 重組抗白介素２３ｐ１９亞基抗體在治療炎症性腸病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130400T1 (en) * 2005-06-30 2013-06-30 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
DK2548577T3 (en) 2005-12-29 2017-03-13 Janssen Biotech Inc HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
US8293883B2 (en) 2007-02-23 2012-10-23 Schering Corporation Engineered anti-IL-23P19 antibodies
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
JP6126532B2 (ja) * 2010-11-04 2017-05-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−２３抗体
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Adv Dig Med，2016年，Vol. 3，p. 88-94
British Journal of Dermatology，2017年，Vol. 177，p. e249, FC31
ClinicalTrials.gov archive，NCT02589665，2018年01月，〈ＵＲＬ：https://clinicaltrials.gov/ct2/history/NCT02589665?A=49&B=49&C=merged#StudyPageTop〉
Inflamm Bowel Dis，2014年，Vol. 20, No. 12，p. 2321-2329

Also Published As

Publication number Publication date
JP2023166388A (ja) 2023-11-21
EA202091989A1 (ru) 2021-01-13
AU2019243283A1 (en) 2020-09-24
IL312807A (en) 2024-07-01
CN111936165A (zh) 2020-11-13
WO2019191464A1 (en) 2019-10-03
IL277514B2 (en) 2024-11-01
TWI744617B (zh) 2021-11-01
MY202368A (en) 2024-04-24
BR112020018099A2 (pt) 2020-12-22
PT3773715T (pt) 2024-05-27
US12152072B2 (en) 2024-11-26
AU2019243283C1 (en) 2024-05-02
SI3773715T1 (sl) 2024-06-28
LT3773715T (lt) 2024-06-25
PL3773715T3 (pl) 2024-08-19
JP7571225B2 (ja) 2024-10-22
TW202206104A (zh) 2022-02-16
KR20200128101A (ko) 2020-11-11
EP4327866A3 (en) 2024-03-20
NZ767902A (en) 2024-05-31
AU2019243283B2 (en) 2023-07-27
TWI837532B (zh) 2024-04-01
JP2022169562A (ja) 2022-11-09
AU2023248103A1 (en) 2023-11-09
ES2983809T3 (es) 2024-10-24
IL312807B1 (en) 2025-02-01
TW201946657A (zh) 2019-12-16
HRP20240904T1 (hr) 2024-10-11
UA128578C2 (uk) 2024-08-21
EP4327866A2 (en) 2024-02-28
EP4327866B1 (en) 2025-12-10
SG11202009526RA (en) 2020-10-29
DK3773715T3 (da) 2024-05-27
ZA202005388B (en) 2025-05-28
IL277514A (en) 2020-11-30
EP3773715B1 (en) 2024-05-08
JP2021517156A (ja) 2021-07-15
US20250034243A1 (en) 2025-01-30
FI3773715T3 (fi) 2024-05-30
JP7331219B2 (ja) 2023-08-22
MA52216A (fr) 2021-02-17
IL277514B1 (en) 2024-07-01
MX2020010269A (es) 2020-11-06
HUE067445T2 (hu) 2024-10-28
JP2025020134A (ja) 2025-02-12
RS65661B1 (sr) 2024-07-31
KR102552693B1 (ko) 2023-07-07
MA52216B1 (fr) 2024-07-31
US20210032325A1 (en) 2021-02-04
EP3773715A1 (en) 2021-02-17
IL312807B2 (en) 2025-06-01
CA3095297A1 (en) 2019-10-03
MD3773715T2 (ro) 2024-10-31

Similar Documents

Publication Publication Date Title
JP7331219B2 (ja) 潰瘍性大腸炎を治療する方法
CN112689512B (zh) 用于治疗银屑病的组合物和方法
JP7297930B2 (ja) クローン病を治療する方法に使用するためのミリキズマブ
HK40101440A (en) Mirikizumab in the treatment of ulcerative colitis
CN114423455A (zh) 用于治疗系统性硬化症的药物组合物
HK40036550B (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550A (en) Mirikizumab in the treatment of ulcerative colitis
EA049081B1 (ru) Способы лечения язвенного колита
TW202500184A (zh) 治療潰瘍性結腸炎之方法
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220803

R150 Certificate of patent or registration of utility model

Ref document number: 7119114

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250